## Parkinson's dyskinesia mechanism explained

## Source: Scripps Research Institute

Summary: The mechanism underlying Parkinson's dyskinesia has been unknown, until now. An international collaboration has found a key cause, and with it, potentially, a new route to providing relief.

Many people with Parkinson's disease eventually develop debilitating movements called dyskinesia, a side effect of their much-needed dopamine replacement medication. The mechanism underlying this unwanted side effect has been unknown, until now. An international collaboration led by Scripps Research, Florida has found a key cause, and with it, potentially, a new route to providing relief.

Dopamine replacement therapy makes Parkinson's symptoms much better at first, but eventually treatment gives way to uncontrollable, jerky body movements. But why? New research shows that underlying this development is the therapy's unintended boost of a protein with the unwieldy name Ras-guanine nucleotide-releasing factor 1, or RasGRP1 for short. This boost in RasGRP1 produces a cascade of effects which lead to abnormal, involuntary movements known as LID, or L-DOPA-induced dyskinesia, says co-lead author Srinivasa Subramaniam, PhD, associate professor of neuroscience at Scripps Research, Florida.

Encouragingly, the collaboration found that in dopamine-depleted mice and other animal models, inhibiting production of RasGRP1 in the brain during dopamine replacement diminished the involuntary movements without negating the useful effects of the dopamine therapy.

Taken together, the research offers a new path to easing Parkinson's dyskinesia while allowing maintenance of dopamine replacement therapy, Subramaniam says.

Subramaniam's group has long been interested in cellular signaling in the brain underlying motor movements, and how it is affected by brain diseases, including Huntington's and Parkinson's.

"Parkinson's patients describe treatment-induced dyskinesia as one of the most debilitating features of their illness," Subramaniam says. "These studies show that if we can down-regulate RasGRP1 signaling before dopamine replacement, we have an opportunity to greatly improve their quality of life."

The study, "RasGRP1 is a causal factor in the development of L-DOPA-induced dyskinesia in Parkinson's disease," published in the journal *Science Advances* May 1. In addition to Subramaniam, the co-lead author is Alessandro Usiello, PhD, of the University of Campania Luigi Vanvitelli, Caserta, Italy, and the Behavioural Neuroscience Laboratory at Ceinge Biotecnologie Avanzate, Naples, Italy.

Dopamine is a neurotransmitter and hormone that plays a key role in movement, learning, memory, motivation, and emotion. Parkinson's develops when dopamine-producing neurons in a region of the mid-brain called the substantia nigra stop working or die. It's a brain region associated with both movement initiation and reward, so its impairment causes a wide variety of symptoms, including stiffness, balance problems, walking difficulty, tremor, depression and memory issues.

Doctors treat Parkinson's with dopamine replacement therapy, often a medicine called levodopa. The brain converts levodopa into dopamine, and at proper doses, this leads to resolution of symptoms. But as dose and duration grow, a side effect called dyskinesia can develop. After a decade, about 95 percent of Parkinson's patients will experience some degree of involuntary dyskinesia, Subramaniam says.

01 maggio 2020

Dyskinesia is different than tremor, according to the Michael J. Fox Foundation.

"It can look like fidgeting, writhing, wriggling, head bobbing or body swaying," the foundation explains. "Many people say they prefer dyskinesia to stiffness or decreased mobility. Others, though, have painful dyskinesia or movements that interfere with exercise or social or daily activities."

The reason for its development has eluded scientists. Subramaniam and his team had studied the problem over the past decade, leading them eventually to the discovery that RasGRP1 signaling was a main culprit.

"There is an immediate need for new therapeutic targets to stop LID, or L-DOPA-induced dyskinesia in Parkinson's disease," Subramaniam says. "The treatments now available work poorly and have many additional unwanted side effects. We believe this represents an important step toward better options for people with Parkinson's."

The next steps in the research will be discovering the best route to selectively reducing expression of RasGRP1 in the striatum while not affecting its expression in other areas of the body, Subramaniam says.

"The good news is that in mice, a total lack of RasGRP1 is not lethal, so we think that blocking RasGRP1 with drugs, or even with gene therapy, may have very little or no major side effects," Subramaniam says.

"It's rare for a nonprofit institution to possess the medicinal chemistry and drug development expertise needed to identify and develop such a therapy, but we have that at Scripps Research," Subramaniam says. "Our next task is to develop suitable compounds capable of blocking RasGRP1 in the striatum."

https://www.sciencedaily.com/releases/2020/05/200501150558.htm

Colonocidany		stlow <b>f f</b> In Subscribe A E				Parkinson's develops when dopamine-producing neurons in a region of the mid-brain called the substantia nigra stop working or
You'r Source for the ladod research news New Arventisevewr			Follow all of ScienceDaily's latest research news and top science headlines!			die. It's a brain region associated with both movement initiation and reward, so its impairment causes a wide variety of symptoms, including stiffness, balance problems, walking difficulty, tremor, depression and memory issues.
D Health - Tach - Enviro - Society - Quirky -		Search Q		٩	Doctors treat Parkinson's with dopamine replacement therapy, often a medicine called levodopa. The brain converts levodopa into dopamine, and at proper doses, this leads to resolution of symptome. But as dose and duration row, a side effect called	
Science News	from research organizations		ê îmi 🖀	E Email 🥐	Share	symptoms. But as dose and duration grow, a side effect cared dvskinesia can develop. After a decade, about 95 percent of
Parkinson's dyskinesia	mechanism explained					Parkinson's patients will experience some degree of involuntary dyskinesia, Subramaniam says.
Dete: May 1, 2020 Source: Scripps Research Institute		Most Popular mis week			15 week	Dyskinesia is different than tremor, according to the Michael J. Fox
Summer: The mechanism underlying Parkinson's dyskinesia has been unknown, until now. An			CINE			Foundation.
International collaboration has found a key cause, and with it, potentially, a new route to providing reliat.		The Best Material for Homemade Face Masks May Be a Combination of Two Fabrics				"It can look like fidgeting, writhing, wriggling, head bobbing or body swaying," the foundation explains. "Many people say they prefer
Share: 🫉 🍠 🖗 in 🚟		AC S	OVID-19 Con as a Natural C	onavirus Epic Origin	Serric .	dyskinesia to stiffness or decreased mobility. Others, though, have painful dyskinesia or movements that interfere with exercise or
RELATED TOMOS PULL	210KY	Loss of Smell a Symptoms in Po	nd Taste Valid	sated as CO	VID-19 v Rate	social or daily activities."
Health & Medicine Ma	Many people with Parkinson's disease eventually	MIND & BRAIN				The reason for its development has eluded scientists.
	elop debilitating movements called dyskinesia, a		yes Send an l	Unexpected	Signal	Subramaniam and his team had studied the problem over the past
	effect of their much-needed dopamine acement medication. The mechanism		the Brain			decade, leading them eventually to the discovery that RasGRP1 signaling was a main culprit.
> Gene Therapy Unc	erlying this unwanted side effect has been		cientists Reco	concelle Neur	one in	
	nown, until now. An international collaboration		cientists Rege lice With Spin ptic Nerve Da		and	"There is an immediate need for new therapeutic targets to stop LID, or L-DOPA-induced dyskinesia in Parkinson's disease."
	by Scripps Research, Florida has found a key se, and with it, potentially, a new route to					Subramaniam says. "The treatments now available work poorly
> Parkinson's pro	viding relief.	🚵 👸 🖁	nk Between C oss	spesity and a	seep	and have many additional unwanted side effects. We believe this
<ul> <li>Disorders and Syndromes</li> </ul>	-					represents an important step toward better options for people with
muc	amine replacement therapy makes Parkinson's symptoms h better at first, but eventually treatment gives way to	LIVING & WELL Boy or Girl? IPs				Parkinson's."
	ntrollable, jarky body movements. But why? New research is that underlying this development is the therapy's	Boy or Girl? It's Some COVID-1				The next steps in the research will be discovering the best route to
ADVENTISEMENT unin	ended boost of a protein with the unwieldy name Ras- ine nucleotide-releasing factor 1, or RasGRP1 for short. This I in RasGRP1 produces a cascade of effects which lead to	After Symptoms Wearing Surgio	s Disappear al Masks in P	ublic Could H		selectively reducing expression of RasGRP1 in the striatum while not affecting its expression in other areas of the body, Reducements of the striature of the s
abro RELATED TERRIS Indu	abnormal, involuntary movements known as LID, or L-DOPM- induced dyskinesia, says co-lead author Srinivasa Subramaniam,		Slow COVID-19 Pandemic's Advance			Subramaniam says. "The good news is that in mice, a total lack of RasGRP1 is not
> Colaboration Flor	, associate professor of neuroscience at Scripps Research, da.	Strange & Offbeat				lethal, so we think that blocking RasGRP1 with drugs, or even with gene therapy, may have very little or no major side effects," Subramaniam says.
	uragingly, the collaboration found that in doparnine-depieted					
	mice and other animal models, inhibiting production of RasGRP1 in the brain during dopamine replacement diminished the		HEALTH & MEDICINE			· · · · · · · · · · · · · · · · · · ·
> PMS invo	untary movements without negating the useful effects of the mine therapy.	Electrical Activit Electrical Fields	ty in Living Or	ganisms Min	ors	"It's rare for a nonprofit institution to possess the medicinal chemistry and drug development expertise needed to identify and
> Glutamic acid	mine therapy. In together, the research offers a new path to easing	Viruses from Faces Can Halo Combat Obesity			estv	chemistry and drug development expertise needed to identify and develop such a therapy, but we have that at Scripps Research."
<ul> <li>Embryonic stem cell</li> <li>Pari</li> </ul>	Parkinson's dyskinesia while allowing maintenance of doparnine		and Diabetes			Subramaniam says. "Our next task is to develop suitable
> Hepatits A repl	cement therapy, Subramaniam says.	How to Put Neu	irons Into Cag	205		compounds capable of blocking RasGRP1 in the striatum."